Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

THIM Hogeschool voor Fysiotherapie heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL. Heb je een vraag, neem dan contact op met helpdesk@thim.nl.

» Andere revante producten voor THIM studenten en medewerkers.

Registreer

Om ook buiten de locaties van THIM, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van THIM.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Netherlands Heart Journal
Gepubliceerd in:

01-06-2010 | Review Article

The new oral anticoagulants

Auteur: F. W. A. Verheugt

Gepubliceerd in: Netherlands Heart Journal | Uitgave 6/2010

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Extract

The yearly incidence of stroke in patients with atrial fibrillation is about 5%,1 which is five times higher than in comparable populations in sinus rhythm. The stroke risk largely depends on the underlying heart disease. In 'lone’ atrial fibrillation (absence of heart disease) the stroke risk is only 0.5% per year,2 whereas in atrial fibrillation associated with rheumatic valvular heart disease such as mitral valve stenosis it is very high. …
vorige artikel Long-term comparison of balloon angioplasty with provisional stenting versus routine stenting in patients with non-ST-elevation acute coronary syndrome
volgende artikel Arrogance and ignorance in assessing scientific quality in a multidisciplinary academic medical centre
Literatuur
1.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke. The Framingham study. Arch Intern Med. 1987;147:1561-4.
2.
Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: A population-based study over three decades. N Engl J Med. 1987;317:669-74.
3.
Lip GY, Hart RG, Conway DS. Antithrombotic therapy for atrial fibrillation.BMJ. 2002;325:1022-5.
4.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70.
5.
De Caterina R, Husted S, Wallentin, L, et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J. 2007;28:880-913.
6.
Van Es RF, Jonker JJC, Verheugt FWA, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002:360:109-13.
7.
Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969-74.
8.
Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161-72.
9.
CURE Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
10.
Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-17.
11.
ACTIVE Investigators. Randomized controlled trial of clopidogrel plus aspirin versus oral anticoagulation in patients with atrial fibrillation: The Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE). Lancet. 2006;367:1903-12.
12.
Verheugt FWA. Good old warfarin for stroke prevention in atrial fibrillation. Lancet. 2006;367:1877-8.
13.
Hellemons BSP, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999;319:175-8.
14.
Garcia D, Hylek E. Stroke prevention in elderly patients with atrial fibrillation. Lancet. 2007;370:460-1.
15.
Mant J, Hobbs R, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503.
16.
SPORTIF-III Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (SPORTIF-III): randomised controlled trial. Lancet.2003;362:1691-8.
17.
Albers GW, Diener HC, Frison L, et al Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293:690-8.
18.
Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116:180-7.
19.
Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-75.
20.
Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet. 2008;372:31-9.
21.
Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-86.
22.
Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD-4). Lancet. 2009;373:1673-80.
23.
Verheugt FWA. Good old warfarin for stroke prevention in atrial fibrillation. Lancet. 2006;367:1877-8.
Metagegevens
Titel
The new oral anticoagulants
Auteur
F. W. A. Verheugt
Publicatiedatum
01-06-2010
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Netherlands Heart Journal / Uitgave 6/2010
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03091782

Andere artikelen Uitgave 6/2010

Ventricular asystole due to inhibition of ventricular backup pacing by a dual chamber pacemaker: possible pitfalls of default settings

  • Case report

Einthoven Dissertation Prize 2010

  • Interuniversity Cardiology Institute of the Netherlands

Sudden cardiac death: what should we tell the family?

  • Editorial

Guideline adherence for antithrombotic therapy in acute coronary syndrome: an overview in Dutch hospitals

  • Original article

The value of the ECG for decision-making at first medical contact in the patient with acute chest pain

  • Original article

Rationale and design of the CAREFUL study

  • Study design article